🚀 VC round data is live in beta, check it out!
United Laboratories International Valuation Multiples
Discover revenue and EBITDA valuation multiples for United Laboratories International and similar public comparables like Kalbe Farma, Organon, Mineralys Therapeutics, Ascentage Pharma Group and more.
United Laboratories International Overview
About United Laboratories International
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
Founded
1990
HQ
Employees
17.0K
Website
Sectors
Financials (LTM)
EV
$2B
United Laboratories International Financials
United Laboratories International reported last 12-month revenue of $2B and EBITDA of $399M.
In the same LTM period, United Laboratories International generated $769M in gross profit, $399M in EBITDA, and $271M in net income.
Revenue (LTM)
United Laboratories International P&L
In the most recent fiscal year, United Laboratories International reported revenue of $2B and EBITDA of $578M.
United Laboratories International expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $769M | XXX | $892M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $399M | XXX | $578M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $271M | XXX | $390M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 19% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
United Laboratories International Stock Performance
United Laboratories International has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
United Laboratories International's stock price is $1.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | -1.7% | XXX | XXX | XXX | $0.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialUnited Laboratories International Valuation Multiples
United Laboratories International trades at 0.9x EV/Revenue multiple, and 4.3x EV/EBITDA.
EV / Revenue (LTM)
United Laboratories International Financial Valuation Multiples
As of April 18, 2026, United Laboratories International has market cap of $3B and EV of $2B.
Equity research analysts estimate United Laboratories International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
United Laboratories International has a P/E ratio of 9.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 4.3x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBIT | 5.4x | XXX | 3.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | 1.9x | XXX | XXX | XXX |
| P/E | 9.3x | XXX | 6.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 8.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified United Laboratories International Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
United Laboratories International Margins & Growth Rates
United Laboratories International's revenue in the last 12 month grew by 1%.
United Laboratories International's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
United Laboratories International's rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
United Laboratories International's rule of X is 14% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
United Laboratories International Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | (5%) | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | (11%) | XXX | (26%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 10% | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
United Laboratories International Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| United Laboratories International | XXX | XXX | XXX | XXX | XXX | XXX |
| Kalbe Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| Organon | XXX | XXX | XXX | XXX | XXX | XXX |
| Mineralys Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ADMA Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
United Laboratories International M&A Activity
United Laboratories International acquired XXX companies to date.
Last acquisition by United Laboratories International was on XXXXXXXX, XXXXX. United Laboratories International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by United Laboratories International
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialUnited Laboratories International Investment Activity
United Laboratories International invested in XXX companies to date.
United Laboratories International made its latest investment on XXXXXXXX, XXXXX. United Laboratories International invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by United Laboratories International
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout United Laboratories International
| When was United Laboratories International founded? | United Laboratories International was founded in 1990. |
| Where is United Laboratories International headquartered? | United Laboratories International is headquartered in India. |
| How many employees does United Laboratories International have? | As of today, United Laboratories International has over 17K employees. |
| Is United Laboratories International publicly listed? | Yes, United Laboratories International is a public company listed on HKEX. |
| What is the stock symbol of United Laboratories International? | United Laboratories International trades under 03933 ticker. |
| When did United Laboratories International go public? | United Laboratories International went public in 2007. |
| Who are competitors of United Laboratories International? | United Laboratories International main competitors are Kalbe Farma, Organon, Mineralys Therapeutics, Ascentage Pharma Group. |
| What is the current market cap of United Laboratories International? | United Laboratories International's current market cap is $3B. |
| What is the current revenue of United Laboratories International? | United Laboratories International's last 12 months revenue is $2B. |
| What is the current revenue growth of United Laboratories International? | United Laboratories International revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of United Laboratories International? | Current revenue multiple of United Laboratories International is 0.9x. |
| Is United Laboratories International profitable? | Yes, United Laboratories International is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of United Laboratories International? | United Laboratories International's last 12 months EBITDA is $399M. |
| What is United Laboratories International's EBITDA margin? | United Laboratories International's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of United Laboratories International? | Current EBITDA multiple of United Laboratories International is 4.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.